Drugs Archives - BCDiabetes

Statins for all?

Living With Diabetes,News & Media,Research

On February 1, 2019, the prestigious medical journal the Lancet published a meta-analysis examining potential benefits the statin and class of medication. The article confirmed and extended the powerful evidence for benefit for the use of statins in people with a previous history of heart disease, stroke and for those with diabetes.  It showed that […]

READ MORE

HCTZ and Risk of Skin Cancer

News & Media

Yesterday Health Canada issued a warning around HCTZ (hydrochlorothiazide), a commonly used diuretic blood pressure lowering medication: The warning was issued because of new evidence suggesting a 4-fold increased risk of non-melanoma skin cancer in individuals who have taken HCTZ for 3+ years. Non-melanoma skin cancer is made up of  basal-cell skin cancer (BCC) & […]

READ MORE

BC is a third-world country when it comes to covering life-saving medication for diabetes

Research

A life saving class of diabetes oral medication, SGLT2 inhibitors, costing less than $3/day, is not covered in British Columbia, but is covered in the rest of Canada.  I asked Dr. Elliott, Medical Director of BCDiabetes.ca for his comments.  Dr. Elliott has already blogged twice on this class of medication (see https://www.bcdiabetes.ca/third-sglt2-inhibitor-in-canada/ & https://www.bcdiabetes.ca/empa-reg-outcome-renal/ Dr. […]

READ MORE

Third SGLT2 inhibitor to be marketed in Canada

Research

Empagliflozin “Jardiance” is the third member of the SGLT2 inhibitor class to be marketed in Canada.  Like the other two members of the class (canagliflozin “Invokana” and dapagliflozin “Forxiga”) it lowers blood sugar and weight by causing wasting of sugar/glucose in the urine.  This results in increased urine volumes in all patients and a tripling […]

READ MORE
Translate »